Cresset Asset Management LLC Sells 3,816 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Cresset Asset Management LLC trimmed its position in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 68.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,734 shares of the biotechnology company's stock after selling 3,816 shares during the period. Cresset Asset Management LLC's holdings in Axon Enterprise were worth $1,031,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. New Wave Wealth Advisors LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at approximately $40,000. Y.D. More Investments Ltd acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at approximately $45,000. Stonebridge Financial Group LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at approximately $53,000. GPS Wealth Strategies Group LLC lifted its position in shares of Axon Enterprise by 74.1% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock valued at $56,000 after buying an additional 40 shares during the last quarter. Finally, Berbice Capital Management LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at approximately $59,000. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Stock Up 1.2%

Shares of NASDAQ AXON opened at $693.10 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise, Inc. has a 52 week low of $273.52 and a 52 week high of $715.99. The stock has a market capitalization of $53.96 billion, a P/E ratio of 179.10, a PEG ratio of 5.17 and a beta of 1.24. The stock's fifty day moving average is $567.67 and its 200 day moving average is $587.57.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The company had revenue of $603.63 million for the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. Axon Enterprise's revenue was up 31.3% on a year-over-year basis. During the same quarter last year, the business earned $1.15 earnings per share. Sell-side analysts forecast that Axon Enterprise, Inc. will post 5.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on AXON shares. Barclays raised their price objective on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research report on Friday. Northcoast Research downgraded Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. JMP Securities reaffirmed an "outperform" rating on shares of Axon Enterprise in a report on Tuesday, February 4th. Craig Hallum cut Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. Finally, Needham & Company LLC increased their price objective on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $640.91.

Insider Activity at Axon Enterprise

In related news, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $540.99, for a total value of $5,409,900.00. Following the sale, the chief executive officer now directly owns 3,063,982 shares of the company's stock, valued at $1,657,583,622.18. This trade represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Jeri Williams sold 307 shares of Axon Enterprise stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $552.72, for a total value of $169,685.04. Following the sale, the director now directly owns 1,627 shares in the company, valued at $899,275.44. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.